Clinical Trials
70 trialsTrimelvax001
University of Chile
Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors
NGM Biopharmaceuticals, Inc
Study Comparing the Pharmacokinetics, Safety, and Efficacy of RPH-075 and Keytruda® in Patients With Malignant Neoplasms
R-Pharm
A Phase 1 Study of GNR-051 in Subjects With Advanced Malignancies
AO GENERIUM
Safety, Tolerability and Pharmacokinetics of a Monoclonal Antibody Specific to B-and T-Lymphocyte Attenuator (BTLA) as Monotherapy and in Combination With an Anti-PD1 Monoclonal Antibody for Injection in Subjects With Advanced Malignancies
TopAlliance Biosciences
ERK Inhibitor JSI-1187 in Advanced Solid Tumors
JS InnoPharm, LLC
Autologous CD8+ SLC45A2-Specific T Lymphocytes With Cyclophosphamide, Aldesleukin, and Ipilimumab in Treating Patients With Metastatic Uveal Melanoma
M.D. Anderson Cancer Center
A Phase I Trial of SIM1811-03 in Subjects With Advanced Tumors
Jiangsu Simcere Pharmaceutical Co., Ltd.
Clinical Trial to Evaluate the PK and Safety of BCD-201 and Keytruda® in Patients With Advanced Malignancies
Biocad
Neo-T in Treating Patients With Advanced Solid Tumors(GI-NeoT-03)
BGI, China
An Exploratory Single-arm Study: PD-1 With Recombinant Human Adenovirus Type 5 Injection for Malignant Melanomas
Fujian Cancer Hospital
First in Human Study of NVG-111 in Relapsed/Refractory ROR1+ Malignancies
NovalGen Ltd.
Efficacy and Safety of TQB2618 Injection Combined With Toripalimab Injection in Patients With Advanced Melanoma
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Arm 1: Lysate Pulsed Dendritic Cells (PV-001-DC) in Patients With Melanoma
PrimeVax Immuno-Oncology Inc.
A Window of Opportunity Trial of Intratumoral Injection of Copaxone® in Patients With Percutaneously Accessible Tumors
University of Kansas Medical Center
Study to Evaluate JCXH-211 as Monotherapy in Patients With Malignant Solid Tumors
Immorna Biotherapeutics, Inc.
Treatment of Advanced Solid Tumors With Neo-T(GI-NeoT-02)
BGI, China
GEN602
Genzada Pharmaceuticals USA, Inc.
A Study to Assess PV-10 Chemoablation of Cancer of the Liver
Provectus Pharmaceuticals
Pembrolizumab Administered Via the Sofusa® DoseConnect™ in Patients With Relapsed/Refractory Cutaneous T-cell Lymphoma.
Sorrento Therapeutics, Inc.
A Phase I Trial of SIM1811-03 in Subjects With Advanced Solid Tumors and Cutaneous T-cell Lymphoma
Jiangsu Simcere Pharmaceutical Co., Ltd.
T Cell Transfer With or Without Dendritic Cell Vaccination in Patients With Melanoma
Karolinska University Hospital
Dose Escalation of RMC-4630 Monotherapy in Relapsed/Refractory Solid Tumors
Revolution Medicines, Inc.
MICROBIOME
Imperial College London
Study of TBX-3400 in Patients With Stage III and IV Melanoma Resistant or Refractory to Immune Checkpoint Inhibitors
Taiga Biotechnologies, Inc.
OpACIN
The Netherlands Cancer Institute
A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549
Infinity Pharmaceuticals, Inc.
Personalized Immune Cell Therapy Targeting Neoantigen of Malignant Solid Tumors
Sichuan University
A Clinical Trial of TAA06 Injection in Advanced Solid Tumors
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Relative Bioavailability of Binimetinib 3 x 15 mg and 45 mg Formulations
Pierre Fabre Medicament
Study of Intratumoral CV8102 in cMEL, cSCC, hnSCC, and ACC
CureVac
Study of Oncolytic Virus in Combination With HX-008 and Axitinib in Melanoma Patients With Liver Metastasis
Peking University Cancer Hospital & Institute
Study of Oncolytic Virus in Combination With HX-008 and Radiotherapy in Melanoma Patients With Liver Metastasis
Peking University Cancer Hospital & Institute
A Phase I Study to Evaluate the Safety, Tolerability and Pharmacokinetics of JS004 in Advanced Solid Tumors
Shanghai Junshi Bioscience Co., Ltd.
Sequentional Immuno Apheresis Plasma Volume Escalation Cohort Study of Reduction of Soluble Tumor Necrosis Factor Receptors 1 and 2 (sTNFR1/2) With or Without Nivolumab in Patients With Inoperable or Metastatic Solid Tumors
Sheba Medical Center
A Study of HX008 Plus LP002 for the Treatment of Patients With Advanced Melanoma
Taizhou HoudeAoke Biomedical Co., Ltd.
Clinical Study to Evaluate OrienX010 in Combination With Toripalimab as Neoadjuvant Treatment in Advanced Melanoma
Peking University Cancer Hospital & Institute
myDCTV
Universitair Ziekenhuis Brussel
Combining Talimogene Laherparepvec With BRAF and MEK Inhibitors in BRAF Mutated Advanced Melanoma
West Cancer Center
Tolerability and Pharmacokinetics of Toripalimab in Combination With Axitinib in Patients With Kidney Cancer and Melanoma
Shanghai Junshi Bioscience Co., Ltd.
A Phase 1 Study of ZSP1602 in Participants With Advanced Solid Tumors
Guangdong Zhongsheng Pharmaceutical Co., Ltd.
A Personalized NeoAntigen Cancer Vaccine Combined With Anti-PD-1 in Melanoma
Xiangya Hospital of Central South University
The Tolerance,Pharmacokinetic Characteristics,Safety and Efficacy of ScTIL210 in the Treatment of Melanoma
Peking University Cancer Hospital & Institute
Study to Evaluate OrienX010 in Combination With JS001 in the Treatment of Stage IV (M1c) Liver Metastasis From Melanoma
Peking University Cancer Hospital & Institute
Topical Fluorescent Nanoparticles Conjugated Somatostatin Analog for Suppression and Bioimaging Breast Cancer
Al-Azhar University
ENIgMA
Cantonal Hospital of St. Gallen
Fecal Microbiota Transplantation (FMT) in Metastatic Melanoma Patients Who Failed Immunotherapy
Sheba Medical Center
Investigator Initiated Phase 1 Study of TBI-1301
Mie University
A Multicenter Open-Label Single-Arm Multi-Cohort Phase I Study of BCD-100 in Patients With Advanced Solid Tumors
Biocad
A Study of BCD-135 in Patients With Advanced Solid Tumors
Biocad